Answers are grounded in this paper and cite their sources.
Cross-sectional study reveals that improved seizure control significantly reduces epilepsy-related stigma.
Background: Epilepsy-related stigma remains a major barrier to care in India. While antiseizure medications (ASMs) are associated with reduced stigma, it remains unclear whether this benefit arises directly from treatment or indirectly through improved seizure control. Methods: We conducted a multisite, cross-sectional study among adults with epilepsy recruited from a tertiary neurology center (All India Institute of Medical Sciences [AIIMS], New Delhi, India) and community outreach clinics in Jharkhand and Madhya Pradesh. Stigma was measured using the validated 24-item Stigma Scale of Epilepsy (SSE), transformed to a 0 to 100 scale. Determinants of stigma were assessed using hierarchical linear regression. Results: The mean global stigma score was 28 (standard deviation 11.6), with felt stigma representing the highest burden (mean 39.9). High seizure burden (≥ weekly seizures) emerged as the strongest predictor of stigma ( β = +25.8, p < 0.001). Additional independent predictors included visible injury during seizures ( β = +8.1, p = 0.001) and unmarried status ( p = 0.03). Treatment compliance showed a significant total effect in reducing stigma ( β = −3.5, p = 0.007). However, this association was substantially attenuated after adjusting for seizure burden, indicating that a large proportion of the treatment effect operates through improved seizure control. Overall, more than half of the observed reduction in stigma among treated individuals was explained by differences in seizure frequency. Conclusion: Epilepsy-related stigma in this setting appears primarily event-driven, shaped by the frequency and visibility of seizures rather than sociodemographic characteristics. The stigma-reducing impact of treatment is largely mediated through seizure control, suggesting that clinical effectiveness is central to achieving social benefit. Interventions that improve access to ASMs and enhance adherence are therefore likely to yield dual gains reducing both seizure burden and stigma. Publication History Article published online: 15 July 2026 © 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Thieme Medical and Scientific Publishers Private Limited A-13A, Graphix Tower 1, 6th floor, Sector 62, Noida 201309, Uttar Pradesh, India
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: